Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy
The world is passing through a very difficult phase due to the coronavirus disease 2019 (COVID-19) pandemic, which has disrupted almost all spheres of life. Globally, according to the latest World Health Organization report (10 August 2020), COVID-19 has affected nearly 20 million lives, causing 728...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Royal Society
2020-09-01
|
| Series: | Open Biology |
| Subjects: | |
| Online Access: | https://royalsocietypublishing.org/doi/pdf/10.1098/rsob.200174 |
| _version_ | 1818858911929729024 |
|---|---|
| author | Ravikant Piyush Keshav Rajarshi Rajni Khan Shashikant Ray |
| author_facet | Ravikant Piyush Keshav Rajarshi Rajni Khan Shashikant Ray |
| author_sort | Ravikant Piyush |
| collection | DOAJ |
| description | The world is passing through a very difficult phase due to the coronavirus disease 2019 (COVID-19) pandemic, which has disrupted almost all spheres of life. Globally, according to the latest World Health Organization report (10 August 2020), COVID-19 has affected nearly 20 million lives, causing 728 013 deaths. Due to the lack of specific therapeutic drugs and vaccines, the outbreak of disease has spawned a corpus of contagious infection all over the world, day by day, without control. As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a very rapid infection rate, it is essential to develop a novel ameliorative and curative strategy as quickly as possible. Convalescent plasma (CP) therapy is a type of adaptive immunity that has already been found to be effective in confronting several infectious diseases from the last two decades. For example, CP therapy was used in the treatment of viral-induced diseases like SARS-CoV epidemics, Middle East respiratory syndrome coronavirus (MERS-CoV) pandemics, Ebola epidemics and H1N1 pandemic. In this review, we have mainly focused on the therapeutic role of CP therapy and its neutralizing effect to fight against the COVID-19 outbreak. |
| first_indexed | 2024-12-19T09:03:49Z |
| format | Article |
| id | doaj.art-291d491281bf4a5e88f6f3a229331c98 |
| institution | Directory Open Access Journal |
| issn | 2046-2441 |
| language | English |
| last_indexed | 2024-12-19T09:03:49Z |
| publishDate | 2020-09-01 |
| publisher | The Royal Society |
| record_format | Article |
| series | Open Biology |
| spelling | doaj.art-291d491281bf4a5e88f6f3a229331c982022-12-21T20:28:24ZengThe Royal SocietyOpen Biology2046-24412020-09-0110910.1098/rsob.200174200174Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategyRavikant PiyushKeshav RajarshiRajni KhanShashikant RayThe world is passing through a very difficult phase due to the coronavirus disease 2019 (COVID-19) pandemic, which has disrupted almost all spheres of life. Globally, according to the latest World Health Organization report (10 August 2020), COVID-19 has affected nearly 20 million lives, causing 728 013 deaths. Due to the lack of specific therapeutic drugs and vaccines, the outbreak of disease has spawned a corpus of contagious infection all over the world, day by day, without control. As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a very rapid infection rate, it is essential to develop a novel ameliorative and curative strategy as quickly as possible. Convalescent plasma (CP) therapy is a type of adaptive immunity that has already been found to be effective in confronting several infectious diseases from the last two decades. For example, CP therapy was used in the treatment of viral-induced diseases like SARS-CoV epidemics, Middle East respiratory syndrome coronavirus (MERS-CoV) pandemics, Ebola epidemics and H1N1 pandemic. In this review, we have mainly focused on the therapeutic role of CP therapy and its neutralizing effect to fight against the COVID-19 outbreak.https://royalsocietypublishing.org/doi/pdf/10.1098/rsob.200174covid-19sars-cov-2plasma therapyviraemiachloroquine |
| spellingShingle | Ravikant Piyush Keshav Rajarshi Rajni Khan Shashikant Ray Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy Open Biology covid-19 sars-cov-2 plasma therapy viraemia chloroquine |
| title | Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy |
| title_full | Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy |
| title_fullStr | Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy |
| title_full_unstemmed | Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy |
| title_short | Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy |
| title_sort | convalescent plasma therapy a promising coronavirus disease 2019 treatment strategy |
| topic | covid-19 sars-cov-2 plasma therapy viraemia chloroquine |
| url | https://royalsocietypublishing.org/doi/pdf/10.1098/rsob.200174 |
| work_keys_str_mv | AT ravikantpiyush convalescentplasmatherapyapromisingcoronavirusdisease2019treatmentstrategy AT keshavrajarshi convalescentplasmatherapyapromisingcoronavirusdisease2019treatmentstrategy AT rajnikhan convalescentplasmatherapyapromisingcoronavirusdisease2019treatmentstrategy AT shashikantray convalescentplasmatherapyapromisingcoronavirusdisease2019treatmentstrategy |